TY - JOUR
T1 - Effect of Rubus Occidentalis Extract on Metabolic Parameters in Subjects with Prediabetes
T2 - A Proof-of-concept, Randomized, Double-blind, Placebo-controlled Clinical Trial
AU - An, Jee Hyun
AU - Kim, Dong Lim
AU - Lee, Tae Bum
AU - Kim, Kyeong Jin
AU - Kim, Sun Hwa
AU - Kim, Nam Hoon
AU - Kim, Hee Young
AU - Choi, Dong Seop
AU - Kim, Sin Gon
N1 - Funding Information:
This study was undertaken as an investigator-initiated research protocol and was supported by a grant of the Gochang Regional Research Institute, Ministry of Trade, Industry and Energy, South Korea. The funding agency had no role in study design, data collection, analysis, interpretation, and preparation of the manuscript or decision to publish.
Publisher Copyright:
Copyright © 2016 John Wiley & Sons, Ltd.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Rubus occidentalis (RO) has beneficial effects on glucose and lipid profiles in vitro. The aim of the study was to investigate RO extract effect on metabolic parameters in prediabetic patients, adopting a 12-week, randomized, double-blind, placebo-controlled trial. Forty-four patients (age 59.0 ± 8.2 years, 70.5% females, HbA1c 5.8 ± 0.4%) were divided into placebo (n = 13), low-dose RO extract (LRE; n = 14), or high-dose RO extract (HRE; n = 17) groups. Either 900 or 1800 mg per day of RO extract was administered orally. Area under the curve for glucose obtained 2 h after a 75-g oral glucose tolerance test was significantly decreased in the HRE group, compared with the placebo group (−28.1 ± 42.4 vs. +13.4 ± 52.6 mg/dL, p < 0.05). Homoeostasis model assessment-B was increased (+17.11 ± 10.69, +5.24 ± 4.10, and +0.86 ± 6.01 in HRE, LRE, and placebo, respectively, p < 0.05). Serum levels of monocyte chemoattractant protein-1 and oxidized low-density lipoprotein were significantly decreased by treatment in a dose-dependent manner (monocyte chemoattractant protein-1: −35.0 ± 21.2, +8.4 ± 18.1, and +24.2 ± 14.5; oxidized low-density lipoprotein: −19.7 ± 8.5, −13.1 ± 7.2, and −2.2 ± 11.0 in the HRE, LRE, and placebo, respectively, p < 0.05). The results support the beneficial effects of RO extract on the control of glycemia and vascular inflammation in prediabetic patients. (ClinicalTrials.gov: NCT01964703).
AB - Rubus occidentalis (RO) has beneficial effects on glucose and lipid profiles in vitro. The aim of the study was to investigate RO extract effect on metabolic parameters in prediabetic patients, adopting a 12-week, randomized, double-blind, placebo-controlled trial. Forty-four patients (age 59.0 ± 8.2 years, 70.5% females, HbA1c 5.8 ± 0.4%) were divided into placebo (n = 13), low-dose RO extract (LRE; n = 14), or high-dose RO extract (HRE; n = 17) groups. Either 900 or 1800 mg per day of RO extract was administered orally. Area under the curve for glucose obtained 2 h after a 75-g oral glucose tolerance test was significantly decreased in the HRE group, compared with the placebo group (−28.1 ± 42.4 vs. +13.4 ± 52.6 mg/dL, p < 0.05). Homoeostasis model assessment-B was increased (+17.11 ± 10.69, +5.24 ± 4.10, and +0.86 ± 6.01 in HRE, LRE, and placebo, respectively, p < 0.05). Serum levels of monocyte chemoattractant protein-1 and oxidized low-density lipoprotein were significantly decreased by treatment in a dose-dependent manner (monocyte chemoattractant protein-1: −35.0 ± 21.2, +8.4 ± 18.1, and +24.2 ± 14.5; oxidized low-density lipoprotein: −19.7 ± 8.5, −13.1 ± 7.2, and −2.2 ± 11.0 in the HRE, LRE, and placebo, respectively, p < 0.05). The results support the beneficial effects of RO extract on the control of glycemia and vascular inflammation in prediabetic patients. (ClinicalTrials.gov: NCT01964703).
KW - Rubus occidentalis
KW - atherosclerosis
KW - black raspberry
KW - metabolic syndrome
KW - prediabetes
UR - http://www.scopus.com/inward/record.url?scp=84973650054&partnerID=8YFLogxK
U2 - 10.1002/ptr.5664
DO - 10.1002/ptr.5664
M3 - Article
C2 - 27279471
AN - SCOPUS:84973650054
SN - 0951-418X
VL - 30
SP - 1634
EP - 1640
JO - Phytotherapy Research
JF - Phytotherapy Research
IS - 10
ER -